Rhofade sold to EPI Health

Written by on October 16, 2019 in research with 0 Comments

Having been sold just 1 year ago to Aclaris, the topical redness treatment for rosacea, Rhofade has again changed hands – this time to EPI Health. The value of the transaction is around $55m. Rhofade was previously owned by Allergan.

What is Rhofade?

Rhofade is Oxymetazoline  HCL 1% Cream for the Redness of Rosacea. Officially it is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

Rhofade Sale Press Release

Aclaris Therapeutics Announces Divestiture of RHOFADE

WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it has divested RHOFADE® (oxymetazoline hydrochloride) cream, 1% (RHOFADE) and related intellectual property assets to EPI Health, LLC (EPI Health).

The divestiture of RHOFADE is a key component of Aclaris’ recently announced strategic plan to refocus resources on the development of its immuno-inflammatory development programs.

Who are EPI Health?

About EPI Health, LLC
Headquartered in Charleston, South Carolina, EPI Health is a specialty pharmaceutical company committed to delivering innovative prescription therapies to dermatologists while improving the quality of life of patients and providing outstanding medical services to dermatology community. EPI Health is a wholly owned subsidiary of EPI Group. For more information, visit the EPI Health website at www.epihealth.com.

What else do EPI Make?

EPI Health manufacture the following products

  • MINOLIRA is a tetracycline-class drug indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
  • Cloderm Cream 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Cloderm Cream 0.1% contains the medium potency topical corticosteroid, clocortolone pivalate, in a specially formulated water washable emollient cream base.
  • Bensal HP is indicated for the external treatment of inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas.
  • Sitavig (acyclovir), 50mg Muco-Adhesive Buccal Tablet is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults
  • Bionect is indicated for the dressing and management of partial to full thickness dermal ulcers (pressure sores, venous stasis ulcers, arterial ulcers, diabetic ulcers); wounds including cuts, abrasions, donor sites and post-operative incisions; irritations of the skin; and first- and second-degree burns.

So it may be a good sign that EPI Health already have a portfolio of treatments for skin conditionas. Lets hope that they remain committed to Rhofade for the long term and continue to invest in future products.

Related Articles

Read more about: research

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.